What is the highest level of Wegovy, and how do you get there?

What does the Wegovy dosing schedule actually look like from start to finish?

Wegovy's schedule is a slow, deliberate climb. It starts at 0.25 mg weekly, a dose whose job is entirely about settling your system rather than driving weight loss. From there the path moves to 0.5 mg, then 1.0 mg, then 1.7 mg, and then the previous maintenance ceiling of 2.4 mg, with each rung held for roughly four weeks. The MHRA's April 2026 approval of the 7.2 mg pen added a further tier, making the full sequence 0.25 → 0.5 → 1.0 → 1.7 → 2.4 → 7.2 mg.

The reason the steps are spaced the way they are is straightforward: semaglutide slows gastric emptying, and going too fast nearly guarantees the kind of nausea and vomiting that makes people stop altogether. Holding each dose for a month gives your digestive system time to adjust. Many people find the side-effect picture at the lower levels already manageable; others take longer. Your prescriber can pause the titration at any point if a particular dose needs more time. If you want to understand what the levels of Wegovy are and what to expect at each stage, the full breakdown covers each step in detail.

Worth knowing: the 7.2 mg pen is reserved for adults with a BMI of 30 or above. It is not part of the licensed indication for people using Wegovy for cardiovascular risk reduction at a lower BMI threshold. A prescriber reviews both your BMI and your response to lower doses before considering it.

How high does Wegovy go compared with other licensed options?

Before April 2026, 2.4 mg was the standard maintenance dose for Wegovy injection, and the trial evidence behind that dose, published in the STEP 1 study in the New England Journal of Medicine, reported roughly 15% average body-weight reduction over 68 weeks. The 7.2 mg approval closes a meaningful gap.

At 7.2 mg, clinical data showed approximately 20.7% average weight loss at 72 weeks, and if you are curious about what the highest Wegovy dose is and how it compares, those figures put it much closer to the results seen with semaglutide programmes at high intensity, and in the same broad range as tirzepatide's headline figures. For context on what sits alongside it, the weight-loss treatment overview sets out the licensed options currently available in the UK.

The MHRA's announcement of the 7.2 mg pen approval on 14 April 2026 confirmed the single-dose auto-injector format: one pre-set weekly injection with a built-in covered needle that locks after use, which makes it functionally identical to using the lower-dose pens. No complex assembly, no dose calculation required on the patient's side.

Crucially, reaching 7.2 mg is not the aim for everyone. A prescriber looks at how much weight you have lost at your current dose, how you are tolerating it, and what your clinical picture looks like. Moving to the highest level is a clinical decision, not a routine next step.

Are there situations where the top dose might not be right?

Yes, and this is where a honest answer matters more than a reassuring one. The highest Wegovy level carries the same gastrointestinal side-effect profile as lower doses, generally amplified. Nausea, loose stools, constipation, reflux and fatigue are the most commonly reported effects; they tend to be most pronounced in the first few weeks after a dose change before settling. If side effects at 2.4 mg were difficult to manage, moving directly to 7.2 mg would need careful prescriber judgement.

Some clinical histories make the higher dose unsuitable or require extra caution. A personal or family history of medullary thyroid carcinoma, a diagnosis of MEN2, a history of pancreatitis, or certain gastrointestinal conditions are among the factors a prescriber considers before any dose, not just the ceiling. The general FAQs cover some of the common eligibility questions in plain terms.

The NICE recommendation for semaglutide (published as TA875) specifies a review point: if you have not lost at least 5% of your body weight after six months at the maintenance dose, continuing is reconsidered. That review logic applies at any maintenance dose, including 7.2 mg.

Storage is the same as for other Wegovy pens: keep it in the fridge at 2–8°C. Plenty of people tuck it in the fridge door, though the exact room-temperature window if you need to travel with it is set out in the Patient Information Leaflet rather than something to guess at.

How does a private consultation factor in when you want to reach the highest dose?

On the NHS, Wegovy is available only through specialist weight management services with multidisciplinary support, and waiting lists in many areas are long. The private route through a regulated pharmacy like our team at nume gives you access to the same licensed medicine without a referral or a wait, provided you meet the clinical criteria.

At nume, every consultation is read by a GPhC-registered Independent Prescriber — a real clinician, on the same day. That includes every repeat order and every request for a dose increase, which requires clinical evidence before the prescriber signs off. You will not be moved to a higher dose automatically; the review is part of the process every time, and that is by design. Our clinical oversight structure sets out how that works in practice.

If you are wondering what levels of Wegovy there are and what the highest might mean for you specifically, the right place to start is a clinical conversation rather than a dose chart. The cost of Wegovy as a private prescription is worth understanding before you begin, since treatment at higher doses reflects the pen's licensed price. For anyone ready to take that first step, a free consultation with our prescribers is where the conversation starts.